Seeking Alpha
28 Feb 2026, 14:47 UTC · 35w ago
Impact · against what's priced in
Emergent BioSolutions faces a significant valuation reset following a sharp downward revision of 2026 revenue and EBITDA guidance. The removal of 2025 one-time tailwinds, combined with structural competitive pressure in the naloxone market, creates a negative outlook for forward earnings.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
Emergent BioSolutions' 2026 revenue guidance is projected at $720–$760 million, which is significantly below previous expectations.
So whatA sharp downward reset in top-line guidance typically leads to an immediate negative re-rating of the stock.
More negative than 99% of claims this week
2026 adjusted EBITDA is guided lower to a range of $135–$155 million.
So whatLowered earnings projections directly impact valuation multiples and investor sentiment regarding profitability.
Continue reading
5 related stories
The company has slashed 2026 revenue guidance to $720–$760 million and adjusted EBITDA to $135–$155 million, while admitting that 2025's $60 million one-time order and cost controls will not recur.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 98% of claims this week
The 2025 profitability gains from cost controls and a one-time $60 million order are not expected to recur in 2026.
More negative than 90% of claims this week
Competitive pressure on naloxone and inconsistent government procurement are driving margin compression.
More negative than 86% of claims this week
Which stocks this story touches
More negative than 93% of ticker scores this week
The company faces a sharp reset in 2026 guidance with projected revenues well below expectations and margin compression due to competitive pressure.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
58m ago
−25.6%
Price agrees with the score
$6.06 vs $8.15 close before publication (Feb 27) · not market-adjusted
EBS chart →
